1-[[3-[(3R)-3-ethyl-4-propanoylpiperazine-1-carbonyl]-4-fluorophenyl]methyl]quinazoline-2,4-dione
C25H27FN4O4 — CID 130293051
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[[3-[(3R)-3-ethyl-4-propanoylpiperazine-1-carbonyl]-4-fluorophenyl]methyl]quinazoline-2,4-dione
1-[[3-[(3R)-3-ethyl-4-propanoylpiperazine-1-carbonyl]-4-fluorophenyl]methyl]quinazoline-2,4-dione (PubChem CID 130293051) has the molecular formula C25H27FN4O4 and a molecular weight of 466.51 g/mol. Its IUPAC name is 1-[[3-[(3R)-3-ethyl-4-propanoylpiperazine-1-carbonyl]-4-fluorophenyl]methyl]quinazoline-2,4-dione.
Molecular Properties
| Compound Name | 1-[[3-[(3R)-3-ethyl-4-propanoylpiperazine-1-carbonyl]-4-fluorophenyl]methyl]quinazoline-2,4-dione |
|---|---|
| PubChem CID | 130293051 |
| Molecular Formula | C25H27FN4O4 |
| Molecular Weight | 466.51 g/mol |
| Exact Mass | 466.20 |
| IUPAC Name | 1-[[3-[(3R)-3-ethyl-4-propanoylpiperazine-1-carbonyl]-4-fluorophenyl]methyl]quinazoline-2,4-dione |
| SMILES | CCC(=O)N1CCN(C(=O)c2cc(Cn3c(=O)[nH]c(=O)c4ccccc43)ccc2F)C[C@H]1CC |
| InChI | InChI=1S/C25H27FN4O4/c1-3-17-15-28(11-12-29(17)22(31)4-2)24(33)19-13-16(9-10-20(19)26)14-30-21-8-6-5-7-18(21)23(32)27-25(30)34/h5-10,13,17H,3-4,11-12,14-15H2,1-2H3,(H,27,32,34)/t17-/m1/s1 |
| InChIKey | RYCVFUGCROLXMH-QGZVFWFLSA-N |
| XLogP | 2.35 |
| TPSA | 95.48 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 34 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 466.51 |
| LogP ≤ 5 | 2.35 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 130293051 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.